Literature DB >> 34157108

Imaging correlates of serum enzyme-linked immunoelectrotransfer blot (EITB) positivity in patients with parenchymal neurocysticercosis: results from 521 patients.

Prabhakaran Vasudevan1, Ranjith K Moorthy1, Grace Rebekah2, Ellen Jackson3,4,5, Betcy Evangeline Pamela1, Subashini Thamizhmaran1, Josephin Manoj1, Anupriya Thanigachalam1, Douglas Drevets6,7, Hélène Carabin3,4,5,8,9, Vedantam Rajshekhar1.   

Abstract

BACKGROUND: The presence of perilesional edema among patients with parenchymal neurocysticercosis (pNCC) of various lesion subtypes has not been correlated with results of serum enzyme-linked immunotransfer blot (EITB) for cysticercal antibodies.
METHODS: In total, 521 patients with pNCC were classified into solitary cysticercus granuloma (SCG), multiple lesions, at least one of which was an enhancing granuloma (GMNCC), solitary calcified cysticercal lesion (SCC) and multiple calcified cysticercal lesions (CMNCC). The proportion of EITB positivity among each lesion subtype and its association with perilesional edema were determined.
RESULTS: There were significantly higher positive EITB results in patients with GMNCC (90/111, 81.1%) compared with other lesion types. Perilesional edema was associated with positive EITB in patients with CMNCC. On univariate analysis, perilesional edema and GMNCC were associated with EITB positivity. On multivariate analysis, only GMNCC (OR 7.5; 95% CI 3.5 to 16.2) was significantly associated with EITB positivity.
CONCLUSIONS: In patients with pNCC, the presence of perilesional edema is associated with a higher probability of a positive EITB result in patients with CMNCC, suggesting a synchronicity in the mechanisms associated with formation of perilesional edema and the antibody response in this subtype. In patients with enhancing granulomas, edema is not an independent predictor of a positive EITB, suggesting that the enhancement itself is associated with a strong antibody response.
© The Author(s) 2021. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Keywords:  antibodies; cysticercus; edema; immunoblotting; neurocysticercosis

Mesh:

Substances:

Year:  2022        PMID: 34157108      PMCID: PMC9076995          DOI: 10.1093/trstmh/trab091

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.455


  27 in total

1.  An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium).

Authors:  V C Tsang; J A Brand; A E Boyer
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

2.  Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India.

Authors:  V Rajshekhar; M Venkat Raghava; V Prabhakaran; A Oommen; J Muliyil
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

3.  Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay.

Authors:  J V Proaño-Narvaez; Antonio Meza-Lucas; Olga Mata-Ruiz; Roberto Carlos García-Jerónimo; Dolores Correa
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  Taenia larvae possess distinct acetylcholinesterase profiles with implications for host cholinergic signalling.

Authors:  Anja de Lange; Ulrich Fabien Prodjinotho; Hayley Tomes; Jana Hagen; Brittany-Amber Jacobs; Katherine Smith; William Horsnell; Chummy Sikasunge; Dorit Hockman; Murray E Selkirk; Clarissa Prazeres da Costa; Joseph Valentino Raimondo
Journal:  PLoS Negl Trop Dis       Date:  2020-12-21

5.  Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study.

Authors:  Theodore E Nash; E Javier Pretell; Andres G Lescano; Javier A Bustos; Robert H Gilman; Armando E Gonzalez; Héctor H Garcia
Journal:  Lancet Neurol       Date:  2008-11-03       Impact factor: 44.182

6.  Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis.

Authors:  M Wilson; R T Bryan; J A Fried; D A Ware; P M Schantz; J B Pilcher; V C Tsang
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

Review 7.  Immunological and molecular diagnosis of cysticercosis.

Authors:  Silvia Rodriguez; Patricia Wilkins; Pierre Dorny
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

8.  Clinical and neuroimaging predictors of seizure recurrence in solitary calcified neurocysticercosis: A prospective observational study.

Authors:  Alok Kumar Singh; Ravindra Kumar Garg; Imran Rizvi; Hardeep Singh Malhotra; Neeraj Kumar; Rakesh Kumar Gupta
Journal:  Epilepsy Res       Date:  2017-09-20       Impact factor: 3.045

9.  Intermittent perilesional edema and contrast enhancement in epilepsy with calcified neurocysticercosis may help to identify the seizure focus.

Authors:  Job Monteiro C Jama-António; Clarissa L Yasuda; Fernando Cendes
Journal:  Epilepsia Open       Date:  2019-05-03

10.  Inflammation is a key risk factor for persistent seizures in neurocysticercosis.

Authors:  Jesica A Herrick; Biswajit Maharathi; Jin Suh Kim; Gerardo G Abundis; Anjali Garg; Isidro Gonzales; Herbert Saavedra; Javier A Bustos; Hector H Garcia; Jeffrey A Loeb
Journal:  Ann Clin Transl Neurol       Date:  2018-04-10       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.